TNF Blockers News and Research

RSS
Hospira announces EC approval of Inflectra, Europe's first biosimilar mAb therapy

Hospira announces EC approval of Inflectra, Europe's first biosimilar mAb therapy

FDA approves Janssen Biotech's SIMPONI ARIATM for infusion for active rheumatoid arthritis

FDA approves Janssen Biotech's SIMPONI ARIATM for infusion for active rheumatoid arthritis

Ulcerative colitis and Crohn’s disease treatments: an interview with Dr Parikh, vice president, general medicine, Takeda

Ulcerative colitis and Crohn’s disease treatments: an interview with Dr Parikh, vice president, general medicine, Takeda

UCB seeks FDA and EMA marketing authorization for Cimzia to treat active psoriatic arthritis

UCB seeks FDA and EMA marketing authorization for Cimzia to treat active psoriatic arthritis

IRHOM2-targeted drugs can effectively treat patients with rheumatoid arthritis

IRHOM2-targeted drugs can effectively treat patients with rheumatoid arthritis

Abbott announces results from HUMIRA clinical studies on ulcerative colitis

Abbott announces results from HUMIRA clinical studies on ulcerative colitis

FDA approves Abbott’s HUMIRA to treat ulcerative colitis

FDA approves Abbott’s HUMIRA to treat ulcerative colitis

Abbott receives FDA approval for Humira to treat ulcerative colitis

Abbott receives FDA approval for Humira to treat ulcerative colitis

Anti-TNFs increase risk for herpes zoster infections in IRD patients

Anti-TNFs increase risk for herpes zoster infections in IRD patients

Abbott announces results from HUMIRA Phase 3 study on axSpA

Abbott announces results from HUMIRA Phase 3 study on axSpA

Abbott to highlight latest investigational research findings on HUMIRA at EULAR 2012

Abbott to highlight latest investigational research findings on HUMIRA at EULAR 2012

Data from Janssen’s SIMPONI Phase 3 study on ulcerative colitis

Data from Janssen’s SIMPONI Phase 3 study on ulcerative colitis

Abbott initiates enrollment in two HUMIRA Phase 3 trials for moderate to severe HS

Abbott initiates enrollment in two HUMIRA Phase 3 trials for moderate to severe HS

EMA CHMP issues positive opinion to MSD's REMICADE for treatment of pediatric UC

EMA CHMP issues positive opinion to MSD's REMICADE for treatment of pediatric UC

UCB initiates EXXELERATE study in rheumatoid arthritis

UCB initiates EXXELERATE study in rheumatoid arthritis

Five-year results from Abbott's HUMIRA ATLAS study on ankylosing spondylitis

Five-year results from Abbott's HUMIRA ATLAS study on ankylosing spondylitis

Abbott announces results from HUMIRA Phase 3 study on axSpA

Abbott announces results from HUMIRA Phase 3 study on axSpA

UCB to sponsor several key sets of Cimzia data on RA at ACR 2011 meeting

UCB to sponsor several key sets of Cimzia data on RA at ACR 2011 meeting

New long-term data from Abbott's HUMIRA plus methotrexate Phase 3 studies on RA

New long-term data from Abbott's HUMIRA plus methotrexate Phase 3 studies on RA

Abbott to highlight latest research findings on HUMIRA at ACR annual meeting

Abbott to highlight latest research findings on HUMIRA at ACR annual meeting